Reviews Conjugated Estrogens Vaginal Cream


No reviews yet.

Premarin Vaginal Cream Drug Description
PREMARIN
(conjugated estrogens) Vaginal Cream

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS AND
PROBABLE DEMENTIA FOR ESTROGEN-ALONE THERAPY
ENDOMETRIAL CANCER
There is an increased risk of endometrial cancer in a woman with a uterus
who uses unopposed estrogens. Adding a progestin to estrogen therapy has been
shown to reduce the risk of endometrial hyperplasia, which may be a precursor
to endometrial cancer. Adequate diagnostic measures, including directed or
random endometrial sampling when indicated, should be undertaken to rule out
malignancy in postmenopausal women with undiagnosed persistent or recurring
abnormal genital bleeding [see WARNINGS AND PRECAUTIONS].

CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA
Estrogen-alone therapy should not be used for the prevention of cardiovascular
disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased
risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50
to 79 years of age) during 7.1 years of treatment with daily oral conjugated
estrogens (CE) [0.625 mg], relative to placebo [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative Memory Study (WHIMS) estrogen-alone ancillary
study of WHI reported an increased risk of developing probable dementia in
postmenopausal women 65 years of age or older during 5.2 years of treatment
with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR
ESTROGEN PLUS PROGESTIN THERAPY
Estrogen plus progestin therapy should not be used for the prevention
of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The WHI estrogen plus progestin substudy reported increased risks of DVT,
pulmonary embolism, stroke and myocardial infarction in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625
mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to
placebo [see WARNINGS AND PRECAUTIONS, and Clinical
Studies].
The WHI estrogen plus progestin substudy also demonstrated an increased
risk of invasive breast cancer [see WARNINGS AND PRECAUTIONS,
and Clinical Studies] .
The WHIMS estrogen plus progestin ancillary study of the WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 4 years of treatment with daily CE (0.625
mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and MPA, and other combinations and dosage forms of estrogens
and progestins.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of vaginal conjugated estrogens (Premarin Vaginal)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin Vaginal Cream »




Each gram of PREMARIN (conjugated estrogens) Vaginal Cream contains 0.625 mg conjugated estrogens, USP in a nonliquefying base containing cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil. PREMARIN Vaginal Cream is applied intravaginally.
PREMARIN Vaginal Cream contains a mixture of conjugated estrogens obtained
exclusively from natural sources, occurring as the sodium salts of water-soluble
estrogen sulfates blended to represent the average composition of material derived
from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium
equilin sulfate. It contains as concomitant components, sodium sulfate conjugates,
17 α-dihydroequilin, 17 α-estradiol, and 17β-dihydroequilin.Last reviewed on RxList: 12/29/2008




Premarin Vaginal Cream Drug Description
PREMARIN
(conjugated estrogens) Vaginal Cream

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS AND
PROBABLE DEMENTIA FOR ESTROGEN-ALONE THERAPY
ENDOMETRIAL CANCER
There is an increased risk of endometrial cancer in a woman with a uterus
who uses unopposed estrogens. Adding a progestin to estrogen therapy has been
shown to reduce the risk of endometrial hyperplasia, which may be a precursor
to endometrial cancer. Adequate diagnostic measures, including directed or
random endometrial sampling when indicated, should be undertaken to rule out
malignancy in postmenopausal women with undiagnosed persistent or recurring
abnormal genital bleeding [see WARNINGS AND PRECAUTIONS].

CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA
Estrogen-alone therapy should not be used for the prevention of cardiovascular
disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased
risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50
to 79 years of age) during 7.1 years of treatment with daily oral conjugated
estrogens (CE) [0.625 mg], relative to placebo [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative Memory Study (WHIMS) estrogen-alone ancillary
study of WHI reported an increased risk of developing probable dementia in
postmenopausal women 65 years of age or older during 5.2 years of treatment
with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR
ESTROGEN PLUS PROGESTIN THERAPY
Estrogen plus progestin therapy should not be used for the prevention
of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The WHI estrogen plus progestin substudy reported increased risks of DVT,
pulmonary embolism, stroke and myocardial infarction in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625
mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to
placebo [see WARNINGS AND PRECAUTIONS, and Clinical
Studies].
The WHI estrogen plus progestin substudy also demonstrated an increased
risk of invasive breast cancer [see WARNINGS AND PRECAUTIONS,
and Clinical Studies] .
The WHIMS estrogen plus progestin ancillary study of the WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 4 years of treatment with daily CE (0.625
mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and MPA, and other combinations and dosage forms of estrogens
and progestins.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of vaginal conjugated estrogens (Premarin Vaginal)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin Vaginal Cream »




Each gram of PREMARIN (conjugated estrogens) Vaginal Cream contains 0.625 mg conjugated estrogens, USP in a nonliquefying base containing cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil. PREMARIN Vaginal Cream is applied intravaginally.
PREMARIN Vaginal Cream contains a mixture of conjugated estrogens obtained
exclusively from natural sources, occurring as the sodium salts of water-soluble
estrogen sulfates blended to represent the average composition of material derived
from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium
equilin sulfate. It contains as concomitant components, sodium sulfate conjugates,
17 α-dihydroequilin, 17 α-estradiol, and 17β-dihydroequilin.Last reviewed on RxList: 12/29/2008




Premarin Vaginal Cream Drug Description
PREMARIN
(conjugated estrogens) Vaginal Cream

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS AND
PROBABLE DEMENTIA FOR ESTROGEN-ALONE THERAPY
ENDOMETRIAL CANCER
There is an increased risk of endometrial cancer in a woman with a uterus
who uses unopposed estrogens. Adding a progestin to estrogen therapy has been
shown to reduce the risk of endometrial hyperplasia, which may be a precursor
to endometrial cancer. Adequate diagnostic measures, including directed or
random endometrial sampling when indicated, should be undertaken to rule out
malignancy in postmenopausal women with undiagnosed persistent or recurring
abnormal genital bleeding [see WARNINGS AND PRECAUTIONS].

CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA
Estrogen-alone therapy should not be used for the prevention of cardiovascular
disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased
risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50
to 79 years of age) during 7.1 years of treatment with daily oral conjugated
estrogens (CE) [0.625 mg], relative to placebo [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative Memory Study (WHIMS) estrogen-alone ancillary
study of WHI reported an increased risk of developing probable dementia in
postmenopausal women 65 years of age or older during 5.2 years of treatment
with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR
ESTROGEN PLUS PROGESTIN THERAPY
Estrogen plus progestin therapy should not be used for the prevention
of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The WHI estrogen plus progestin substudy reported increased risks of DVT,
pulmonary embolism, stroke and myocardial infarction in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625
mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to
placebo [see WARNINGS AND PRECAUTIONS, and Clinical
Studies].
The WHI estrogen plus progestin substudy also demonstrated an increased
risk of invasive breast cancer [see WARNINGS AND PRECAUTIONS,
and Clinical Studies] .
The WHIMS estrogen plus progestin ancillary study of the WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 4 years of treatment with daily CE (0.625
mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and MPA, and other combinations and dosage forms of estrogens
and progestins.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of vaginal conjugated estrogens (Premarin Vaginal)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin Vaginal Cream »




Each gram of PREMARIN (conjugated estrogens) Vaginal Cream contains 0.625 mg conjugated estrogens, USP in a nonliquefying base containing cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil. PREMARIN Vaginal Cream is applied intravaginally.
PREMARIN Vaginal Cream contains a mixture of conjugated estrogens obtained
exclusively from natural sources, occurring as the sodium salts of water-soluble
estrogen sulfates blended to represent the average composition of material derived
from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium
equilin sulfate. It contains as concomitant components, sodium sulfate conjugates,
17 α-dihydroequilin, 17 α-estradiol, and 17β-dihydroequilin.Last reviewed on RxList: 12/29/2008




Premarin Vaginal Cream Drug Description
PREMARIN
(conjugated estrogens) Vaginal Cream

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS AND
PROBABLE DEMENTIA FOR ESTROGEN-ALONE THERAPY
ENDOMETRIAL CANCER
There is an increased risk of endometrial cancer in a woman with a uterus
who uses unopposed estrogens. Adding a progestin to estrogen therapy has been
shown to reduce the risk of endometrial hyperplasia, which may be a precursor
to endometrial cancer. Adequate diagnostic measures, including directed or
random endometrial sampling when indicated, should be undertaken to rule out
malignancy in postmenopausal women with undiagnosed persistent or recurring
abnormal genital bleeding [see WARNINGS AND PRECAUTIONS].

CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA
Estrogen-alone therapy should not be used for the prevention of cardiovascular
disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased
risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50
to 79 years of age) during 7.1 years of treatment with daily oral conjugated
estrogens (CE) [0.625 mg], relative to placebo [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative Memory Study (WHIMS) estrogen-alone ancillary
study of WHI reported an increased risk of developing probable dementia in
postmenopausal women 65 years of age or older during 5.2 years of treatment
with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR
ESTROGEN PLUS PROGESTIN THERAPY
Estrogen plus progestin therapy should not be used for the prevention
of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The WHI estrogen plus progestin substudy reported increased risks of DVT,
pulmonary embolism, stroke and myocardial infarction in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625
mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to
placebo [see WARNINGS AND PRECAUTIONS, and Clinical
Studies].
The WHI estrogen plus progestin substudy also demonstrated an increased
risk of invasive breast cancer [see WARNINGS AND PRECAUTIONS,
and Clinical Studies] .
The WHIMS estrogen plus progestin ancillary study of the WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 4 years of treatment with daily CE (0.625
mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and MPA, and other combinations and dosage forms of estrogens
and progestins.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of vaginal conjugated estrogens (Premarin Vaginal)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin Vaginal Cream »




Each gram of PREMARIN (conjugated estrogens) Vaginal Cream contains 0.625 mg conjugated estrogens, USP in a nonliquefying base containing cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil. PREMARIN Vaginal Cream is applied intravaginally.
PREMARIN Vaginal Cream contains a mixture of conjugated estrogens obtained
exclusively from natural sources, occurring as the sodium salts of water-soluble
estrogen sulfates blended to represent the average composition of material derived
from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium
equilin sulfate. It contains as concomitant components, sodium sulfate conjugates,
17 α-dihydroequilin, 17 α-estradiol, and 17β-dihydroequilin.Last reviewed on RxList: 12/29/2008




Premarin Vaginal Cream Drug Description
PREMARIN
(conjugated estrogens) Vaginal Cream

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS AND
PROBABLE DEMENTIA FOR ESTROGEN-ALONE THERAPY
ENDOMETRIAL CANCER
There is an increased risk of endometrial cancer in a woman with a uterus
who uses unopposed estrogens. Adding a progestin to estrogen therapy has been
shown to reduce the risk of endometrial hyperplasia, which may be a precursor
to endometrial cancer. Adequate diagnostic measures, including directed or
random endometrial sampling when indicated, should be undertaken to rule out
malignancy in postmenopausal women with undiagnosed persistent or recurring
abnormal genital bleeding [see WARNINGS AND PRECAUTIONS].

CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA
Estrogen-alone therapy should not be used for the prevention of cardiovascular
disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased
risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50
to 79 years of age) during 7.1 years of treatment with daily oral conjugated
estrogens (CE) [0.625 mg], relative to placebo [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The Women's Health Initiative Memory Study (WHIMS) estrogen-alone ancillary
study of WHI reported an increased risk of developing probable dementia in
postmenopausal women 65 years of age or older during 5.2 years of treatment
with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR
ESTROGEN PLUS PROGESTIN THERAPY
Estrogen plus progestin therapy should not be used for the prevention
of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS,
and Clinical Studies].
The WHI estrogen plus progestin substudy reported increased risks of DVT,
pulmonary embolism, stroke and myocardial infarction in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625
mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to
placebo [see WARNINGS AND PRECAUTIONS, and Clinical
Studies].
The WHI estrogen plus progestin substudy also demonstrated an increased
risk of invasive breast cancer [see WARNINGS AND PRECAUTIONS,
and Clinical Studies] .
The WHIMS estrogen plus progestin ancillary study of the WHI, reported
an increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 4 years of treatment with daily CE (0.625
mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS,
Use in Specific Populations, and Clinical
Studies].
In the absence of comparable data, these risks should be assumed to be similar
for other doses of CE and MPA, and other combinations and dosage forms of estrogens
and progestins.
Estrogens with or without progestins should be prescribed at the lowest
effective doses and for the shortest duration consistent with treatment goals
and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of vaginal conjugated estrogens (Premarin Vaginal)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden...
Read All Potential Side Effects for Premarin Vaginal Cream »




Each gram of PREMARIN (conjugated estrogens) Vaginal Cream contains 0.625 mg conjugated estrogens, USP in a nonliquefying base containing cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil. PREMARIN Vaginal Cream is applied intravaginally.
PREMARIN Vaginal Cream contains a mixture of conjugated estrogens obtained
exclusively from natural sources, occurring as the sodium salts of water-soluble
estrogen sulfates blended to represent the average composition of material derived
from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium
equilin sulfate. It contains as concomitant components, sodium sulfate conjugates,
17 α-dihydroequilin, 17 α-estradiol, and 17β-dihydroequilin.Last reviewed on RxList: 12/29/2008





Other reviews about Conjugated Estrogens Vaginal Cream on wordpress

Natural Hormones - Are They a Safe Alternative?
  by Gillian Sanson
by Amy Allina and Adriane Fugh-Berman In the wake of the recent news about the risks of estrogen/progestin hormone replacement therapy (HRT), many women are looking to so-called "natural" […]


Frankly Speaking
  by idotrcfc
Updated Mon., Oct. 1 2007*Frank Padilla's response at the bottom.This will be the start of another very interesting multi-part entry.I initially saw the questions posed to Frank in […]


Postmenopausal hormone therapy
  by hijadoo
DEFINING MENOPAUSE — With the onset of menopause, a woman's body stops making estrogen and progesterone. Estrogen and progesterone are the female hormones produced by the ovaries that […]


Postmenopausal hormone therapy
  by hijadoo
DEFINING MENOPAUSE — With the onset of menopause, a woman's body stops making estrogen and progesterone. Estrogen and progesterone are the female hormones produced by the ovaries that […]


FDA Approved Bioidentical Hormones
  by bodylogicmd
We've mentioned that the FDA has approved over 20 bioidentical hormones and now want to share some of the hormones on that list, specifically those meant to treat […]


Hormone Replacement
  by sarasotawellnesscenter
Hormones are chemical messengers produced in our hormone producing glands. They profoundly affect the metabolism of our body, our general health, our brain, heart, bones, muscles, and reproductive […]


Premarin® - A Timeline
  by Vivian
Menopause – The “Disease” Page 1 1686: Fourteen “witches” are executed at Salem – thirteen of them are menopausal women. 1821: A French physician named de Gardanne coins the term […]


What You Can Do
  by Vivian
HOW YOU CAN HELP Talk to Your Doctor Talk to your doctor. Ask him not to prescribe any of the Premarin® family of drugs, and explain why. You […]


What are true natural hormones
  by Kyneth Superioridad
There seems to be a lot of confusion around the definition of "natural" versus "bioidentical” versus "synthetic" hormones. One thing to remember when making this distinction is that […]


He did enter Doctor Hadleys off
  by bkwjsfswcnsviog
_ ACT I _Ten thousand years have passed, and it is the time of the early voyaging from Europe […]



Other reviews about Conjugated Estrogens Vaginal Cream on web:

Medical information about Menopause therapies, symptoms and treatment. conjugated estrogens vaginal cream - Menopause: Menopausal Health ...


Conjugated Estrogens vaginal cream To return to the main entry click here . What is conjugated estrogens vaginal cream? CONJUGATED ESTROGENS Conjugated Estrogens vaginal cream: Information from Answers.com


Conjugated Estrogens Vaginal cream To return to the main entry click here . What is this medicine? CONJUGATED ESTROGENS (CON ju gate ed ESS troe Conjugated Estrogens Vaginal cream: Information from Answers.com


FDA, MedWatch, November 2008 Safety Related Labeling Changes Premarin (conjugated estrogens) Vaginal Cream


Learn about the prescription medication Premarin Vaginal Cream (Conjugated Estrogens Vaginal Cream), drug uses, dosage, side effects, drug interactions, warnings, reviews and ... Premarin Vaginal Cream (Conjugated Estrogens Vaginal Cream) Drug ...


Consumer information about the medication ESTROGENS (CONJUGATED) - VAGINAL CREAM , includes side effects, drug interactions, recommended dosages, and storage information. Read ... ESTROGENS (CONJUGATED) - VAGINAL CREAM side effects, medical uses ...


Conjugated Estrogens Cream increases the chances of getting cancer of the uterus. Report any unusual vaginal bleeding right away while using Conjugated Estrogens Cream. Conjugated Estrogens Cream Facts and Comparisons at Drugs.com


Premarin (Conjugated Estrogens Vaginal Cream) by ABC online pharmacy. Offers the most competitive prices on Premarin (Conjugated Estrogens Vaginal Cream). The most trusted Premarin ... Buy Premarin (Conjugated Estrogens Vaginal Cream) at Online Canada ...


CONJUGATED ESTROGENS (CON ju gate ed ESS troe jenz) are a mixture of female hormones. This cream can help relieve symptoms associated with menopause.like vaginal dryness and ... Conjugated Estrogens


Possible side effects of conjugated estrogens vaginal cream are not just vaginal in nature. This eMedTV page takes an in-depth look at some of the common side effects of the ... Side Effects of Conjugated Estrogens Vaginal Cream





Featured Reviews

Reviews Olanzapine

Zyprexa Drug Description ZYPREXA (olanzapine) Tablet for Oral use ZYPREXA ZYDIS (olanzapine) Tablet, Orally Disintegrating for Oral use ZYPREXA IntraMuscular (olanzapine) Injection, Powder, For Solution for Intramuscular use INCREASED...
Read More  |  Review This
Reviews Antihemophilic Factor

Recombinate Drug Description RECOMBINATE Antihemophilic Factor (Recombinant) DRUG DESCRIPTION RECOMBINATE, Antihemophilic Factor (Recombinant) (rAHF) is a glycoprotein synthesized by a genetically engineered Chinese Hamster Ovary (CHO)...
Read More  |  Review This
Reviews Gris Peg

Gris Peg Drug Description Gris-PEG® (griseofulvin ultramicrosize) Tablets, USP 125 mg; 250 mg DRUG DESCRIPTION What are the possible side effects of griseofulvin? Stop taking griseofulvin and seek emergency medical attention...
Read More  |  Review This
Reviews Alocril

Alocril Drug Description ALOCRIL® (nedocromil sodium) Ophthalmic Solution 2% sterile DRUG DESCRIPTION What are the possible side effects of nedocromil ophthalmic (Alocril)? Serious side effects are not expected with this medication. Les...
Read More  |  Review This
Reviews Trisenox

Trisenox Drug Description Trisenox (arsenic trioxide) Injection For Intravenous Use Only 10 mg/10 mL (1 mg/mL) Ampule WARNING Experienced Physician and Institution TRISENOX (arsenic trioxide) injection should be administered...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....